TURRISI-1999-INT-0096

Regimen

Experimental
45 Gy twice daily over 3 weeks (BID) + cisplatin/etoposide
Control
45 Gy once daily over 5 weeks (QD) + cisplatin/etoposide

Population

Patients with limited small-cell lung cancer treated concurrently with cisplatin-etoposide x4 cycles

Key finding

mOS 23 mo (BID) vs 19 mo (QD), p=0.04; 2-yr OS 47% vs 41%; 5-yr OS 26% vs 16%; grade 3 esophagitis 27% vs 11% (p<0.001)

Source: PMID 9920950

Timeline

    Guideline citations

    • NCCN SCLC (p.28)
    • CSCO SCLC 2025 (p.47)⚠️ OCR source